| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 1,978 | - |
| Bad debt expense | 3 | 1 |
| Depreciation | 7 | 5 |
| Amortization of debt issuance costs and discounts | 189 | 135 |
| Loss on extinguishment of debt | - | -32 |
| Stock-based compensation | 352 | 330 |
| Change in fair value of derivative liability | 46 | 83 |
| Amortization of lease right-of-use-asset | 72 | 47 |
| Loss on extinguishment of debt | -138 | - |
| Net loss | - | -1,236 |
| Gain from forgiveness of debt | 46 | 31 |
| Other non-cash expenses | 21 | 13 |
| Accounts receivable | 7 | 7 |
| Inventory | -50 | -38 |
| Other current assets | -175 | -150 |
| Accounts payable and accrued liabilities | 531 | 327 |
| Lease liabilities | -78 | -51 |
| Deferred revenue | -160 | -170 |
| Net cash used in operating activities | -777 | -500 |
| Purchase of property and equipment | 2 | - |
| Net cash used for investing activities | -2 | - |
| Proceeds from private placement offerings | 260 | - |
| Proceeds from the issuance of notes payable | 463 | 355 |
| Proceeds from the issuance of notes payable issued to related parties | 160 | - |
| Payments made on notes payable | 312 | 218 |
| Payments of debt issuance costs | - | 45 |
| Payments made on notes payable issued to related parties | 31 | - |
| Proceeds from private placement offering | - | 205 |
| Payments of debt issuance costs | 62 | - |
| Net cash provided by financing activities | 478 | 297 |
| Net change in cash | -301 | -203 |
| Cash and cash equivalents at beginning of period | 388 | - |
| Cash and cash equivalents at end of period | 87 | - |
GUIDED THERAPEUTICS INC (GTHP)
GUIDED THERAPEUTICS INC (GTHP)